The identification of metastatic disease by immunohistochemical techniques is labor-intensive and costly. Although it identifies more cases of metastatic disease, the clinical implications for those patients selected are unclear. Despite the utility of sentinel node biopsies in diseases such as breast cancer and melanoma, sentinel node staging has no current value in colon cancer. Overall the utilization of IHC remains investigational.
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